ONO-4538 Phase 2 study (ONO-4538-88/TASUKI-88)
Phase 2
Completed
- Conditions
- Malignancies (Gastric Cancer/Non-Small Cell Lung Cancer)
- Registration Number
- JPRN-jRCT2080225262
- Lead Sponsor
- ONO PHARMACEUTICAL CO., LTD.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
1.Patients with driver mutation/translocation-negative, refractory to radical radiation, and stage IIIB/IIIC/IV or recurrent non-small cell lung cancer and patients with unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer).
2.ECOG Performance Status of 0-1
3.Patients with life expectancy of at least 90 days
Exclusion Criteria
1. Patients with multiple cancers
2. Complication or history of severe hypersensitivity reactions to antibodies and any other drugs
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method efficacy<br>Overall response rate
- Secondary Outcome Measures
Name Time Method safety<br>efficacy<br>Progression-free survival, Overall survival